肥胖对流感疫苗免疫原性影响的系统综述
该系统综述评估肥胖与非肥胖人群接种许可流感疫苗后免疫原性的关联,检索PubMed、Embase和Scopus至2025年2月21日,纳入11项研究。Meta分析显示肥胖与甲型H1N1血清转化或血清保护 marginally 较高可能性相关,甲型H3N2血清转化 marginally 较高,乙型流感无显著差异。结论认为肥胖不损害接种后一个月疫苗免疫,可能增强抗体反应。
要点
- 肥胖与甲型H1N1血清转化或血清保护 marginally 较高可能性相关。
- 肥胖与甲型H3N2血清转化 marginally 较高相关。
- 乙型Victoria和Yamagata株未见显著差异。
核心结论
- 肥胖不损害接种后一个月的流感疫苗免疫,可能增强抗体反应,潜在原因可能是促炎免疫特征。
研究设计与样本
- 系统综述,检索PubMed、Embase和Scopus,最终检索完成于2025年2月21日,方案注册于PROSPERO,由两名评审者在Covidence中完成研究筛选、数据提取和批判性评价,在Stata 17中使用随机效应模型进行Meta分析。
- 纳入报告肥胖与非肥胖受种者接种许可流感疫苗后血清保护(SP)和/或血清转化(SC)的研究,共11项研究报告接种后1个月单价H1N1(n=1)、三价(n=6)或四价(n=4)流感疫苗的结局。
- 研究纳入儿童(n=5)和成人(n=7),包括孕妇(n=2),研究样本量从44到1132名参与者不等。
主要发现
- 肥胖与甲型H1N1血清转化或血清保护 marginally 较高可能性相关(RR 1.04,95%CI 1.01-1.08;RR 1.08,95%CI 1.02-1.14)。
- 肥胖与甲型H3N2血清转化 marginally 较高相关(RR 1.11,95%CI 1.02-1.21)。
- 乙型Victoria和B/Yamagata株未见显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza vaccines are important for reducing the burden of influenza, particularly for populations at risk of more severe infections. Obesity is associated with increased influenza severity and therefore individuals with obesity are often specifically recommended for annual influenza vaccination. Obesity is also associated with an altered inflammatory profile, which may influence vaccine responses. This systematic review aimed to evaluate the evidence for any association between obesity and influenza vaccine immunogenicity. METHODS: Studies reporting seroprotection (SP) and/or seroconversion (SC) for obese vs non-obese recipients following licensed influenza vaccination were included. PubMed, Embase and Scopus were searched, with the final search completed on 21 Feb 2025. The protocol was registered in PROSPERO. Study selection, data extraction and critical appraisal were conducted by two reviewers in Covidence. Meta-analysis was performed in S tata 17 using a random-effects model. RESULTS: Of 2132 studies imported, 865 studies were screened and 140 underwent full-text review. Eleven studies reported outcomes for seroprotection and/or seroconversion for obese vs non-obese groups at 1-month following monovalent H1N1 (n = 1), trivalent (n = 6) or quadrivalent (n = 4) influenza vaccination. Studies included children (n = 5) and adults (n = 7) including pregnant women (n = 2). Study sample sizes varied from 44 to 1132 participants. Obesity was associated with a marginally higher likelihood of seroconversion or seroprotection for A/H1N1 (RR 1.04, 95 %CI 1.01-1.08; RR 1.08, 95 % CI 1.02-1.14) and marginally higher seroconversion for A/H3N2 strains (RR 1.11, 95 % CI 1.02-1.21). No significant differences were observed for Influenza B/Victoria and B/Yamagata strains. CONCLUSIONS: Obesity does not impair influenza vaccine immunity at one-month post-vaccination, and may enhance antibody responses, potentially due to a proinflammatory immune profile.
引用
- Clarke M, McMillan M, Giles LC, et al. The impact of obesity on influenza Vaccine immunogenicity: A systematic review. Vaccine. 2025. PMID: 41033261. doi:10.1016/j.vaccine.2025.127794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。